Program Goals Disclaimer Overview Assessing Disease Activity.

Slides:



Advertisements
Similar presentations
Ethics in Information Technology, Second Edition 1 Ethics in Information Technology, Second Edition (cont.) Chapter 1 An Overview of Ethics.
Advertisements

A POCKET GUIDE TO PUBLIC SPEAKING 4 TH EDITION Chapter 36 Nursing and Allied Health Courses.
Applying the New Multiple Sclerosis Guidelines to Clinical Practice
Introduction to Biosimilars
Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.
Monitoring and Management of Adult Relapsed/Refractory Acute Promyelocytic Leukemia.
Perspectives on Triple-Negative Breast Cancer
Starting Strong: Initial Evaluation of the Patient With HCV
MS Highlights From the 2017 Annual Neurology Meeting
Improving the Diagnosis and Treatment of Seizures in Long-term Care
Program Goals Teriflunomide: Pooled Safety Data.
Risk Stratification in PAH: What Do the Latest Data Suggest?
Updates in Hodgkin Lymphoma
Glaucoma Progression.
Overview of Disparities
Current Controversies in Multiple Sclerosis Management
Charting Progress in MS Diagnosis and Treatment for Today and Tomorrow
Epilepsy Treatment Across the Spectrum
Assessing and Modifying Risks for Older Drivers
New Challenges Facing Multiple Sclerosis Nurses
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?
Individualizing Prophylaxis in Hemophilia
Clinical Cases in Glaucoma Treatment
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Decision-making in the eRA of Treating to Target
Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS
Dispelling Myths and Misconceptions ACC/AHA 2013 Digoxin Guidelines for Heart Failure.
Are We Closer to Personalized Medicine in MS?
Management Challenges in CLL
Management of Adolescents With Seizures
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Charting Progress in MS Treatment:
Poor Response to Initial Therapy for Migraine
ADVANCED PARKINSON'S DISEASE:
Improving Therapeutic Management of Huntington's Disease in Long-Term Care.
Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.
Advancing the Treatment of IBD With Biologics
Treating to Target in MS
New Recommendations on How to Stage Hidradenitis Suppurativa
Primary Biliary Cholangitis
When Is Biologic Therapy Appropriate for HS?
What's New on Interventions for Lower Limb Spasticity?
Traditional Stimulants vs Other Wake-Promoting Agents
Updates in the Management of Parkinson's Disease Psychosis
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Navigating Treatment Options in PAH
Program Goals Overview Is NEDA a Reasonable Target?
Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.
Treatment of Locally Advanced Pancreatic Cancer
Program Goals Disclaimers Defining Refractory Seizures.
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
Insulin in Diabetes Management: Effective Patient Selection Is Key
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
Optimizing Joint Health in Hemophilia
Communicating With Your Patients About Major Depressive Disorder
Incorporating Prostacyclins Into Practice
Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.
Clinical Challenges and Updates in Managing Seizure Clusters
Program Goal. Program Goal Disclaimer Overview.
5 Good Minutes on Atrial Fibrillation-related Stroke
Program Goals Overview Is NEDA a Reasonable Target?
Selecting Treatment Approaches in Hemophilia
Oral Therapies in MS.
Issues in Patients With Severe Epilepsy
At the Crossroads of Coagulation
The Building Blocks of Homocystinuria and Homocysteinemia Management
Treating Pulmonary Embolism Today
Presentation transcript:

Program Goals

Disclaimer

Overview

Assessing Disease Activity

Assessing Disease Activity (cont)

Surveillance Monitoring

Modified Rio Score

How Much Time Should Be Allowed to Determine Whether a DMT Is Effective?

Does Switching Work?

Stopping Natalizumab Treatment

Tolerability Issues

JCV Serology

Is a Washout Period Needed?

Is a Washout Period Needed? (cont)

Rebound

Selecting the Next Treatment Option: General Principles

Guidelines About Switching Are Lacking

Summary and Key Points

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)